MTOR and acute myeloid leukemia: Therefore, the synergistic effect of CC-90009 and quizartinib ormidostaurin may partly stem from FLT3 inhibitors reducing downstream mTOR signaling,thus enhancing the efficacy of CC-90009 in FLT3-ITD-positive AML cells.